{"id":"https://openalex.org/W7204691393","doi":"https://doi.org/10.1016/s2152-2650(26)02850-8","title":"MM-263: Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity","display_name":"MM-263: Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity","publication_year":2026,"publication_date":"2026-08-01","ids":{"openalex":"https://openalex.org/W7204691393","doi":"https://doi.org/10.1016/s2152-2650(26)02850-8"},"language":"en","primary_location":{"id":"doi:10.1016/s2152-2650(26)02850-8","doi":"https://doi.org/10.1016/s2152-2650(26)02850-8","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)02850-8","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.researchsquare.com/article/rs-9707641/latest.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068204824","display_name":"Mahboob Younus Shaik","orcid":"https://orcid.org/0009-0000-9438-6589","observed_orcids":["https://orcid.org/0009-0000-9438-6589"]},"institutions":[{"id":"https://openalex.org/I4210124418","display_name":"CHI St. Vincent","ror":"https://ror.org/02tr0ps12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210124418"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mahboob Younus Shaik","raw_affiliation_strings":["CHI St Vincent Hospital, Hot Springs, AR, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHI St Vincent Hospital, Hot Springs, AR, United States of America","institution_ids":["https://openalex.org/I4210124418"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108885836","display_name":"Sana Dugan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124418","display_name":"CHI St. Vincent","ror":"https://ror.org/02tr0ps12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210124418"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sana Dugan","raw_affiliation_strings":["CHI St Vincent Hospital, Hot Springs, AR, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHI St Vincent Hospital, Hot Springs, AR, United States of America","institution_ids":["https://openalex.org/I4210124418"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5148721079","display_name":"Ashley Jenkins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210124418","display_name":"CHI St. Vincent","ror":"https://ror.org/02tr0ps12","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210124418"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ashley Jenkins","raw_affiliation_strings":["CHI St Vincent Hospital, Hot Springs, AR, United States of America"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CHI St Vincent Hospital, Hot Springs, AR, United States of America","institution_ids":["https://openalex.org/I4210124418"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4210124418"],"apc_list":{"value":3890,"currency":"USD","value_usd":3890},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":null,"first_page":"S1066","last_page":"S1067"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-multiple-myeloma","display_name":"relapsed/refractory multiple myeloma","score":0.9139999747276306},{"id":"https://openalex.org/keywords/bispecific-antibodies","display_name":"bispecific antibodies","score":0.9610000252723694},{"id":"https://openalex.org/keywords/teclistamab","display_name":"teclistamab","score":0.9509999752044678},{"id":"https://openalex.org/keywords/elranatamab","display_name":"elranatamab","score":0.9879999756813049},{"id":"https://openalex.org/keywords/talquetamab","display_name":"talquetamab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/b-cell-maturation-antigen","display_name":"BCMA","score":0.9639999866485596},{"id":"https://openalex.org/keywords/gprc5d","display_name":"GPRC5D","score":0.9980000257492065},{"id":"https://openalex.org/keywords/hypogammaglobulinemia","display_name":"hypogammaglobulinemia","score":0.9940000176429749},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.753000020980835},{"id":"https://openalex.org/keywords/overall-response-rate","display_name":"overall response rate","score":0.7639999985694885},{"id":"https://openalex.org/keywords/dose-de-escalation","display_name":"dose de-escalation","score":0.753000020980835},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6349999904632568},{"id":"https://openalex.org/keywords/maintenance-of-response","display_name":"response maintenance","score":0.46299999952316284},{"id":"https://openalex.org/keywords/t-cell-exhaustion","display_name":"T cell exhaustion","score":0.47999998927116394}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9653000235557556},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.7315000295639038},{"id":"https://openalex.org/C3020495827","wikidata":"https://www.wikidata.org/wiki/Q426141","display_name":"Bispecific antibody","level":4,"score":0.6430000066757202},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6126999855041504},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4878000020980835},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.44110000133514404},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3345000147819519},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.32919999957084656},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.29750001430511475},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.29120001196861267},{"id":"https://openalex.org/C2777334693","wikidata":"https://www.wikidata.org/wiki/Q659446","display_name":"Maximum tolerated dose","level":3,"score":0.2648000121116638},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.2614000141620636},{"id":"https://openalex.org/C2908856526","wikidata":"https://www.wikidata.org/wiki/Q16252627","display_name":"Antibody therapy","level":4,"score":0.2605000138282776},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.2587999999523163},{"id":"https://openalex.org/C194409129","wikidata":"https://www.wikidata.org/wiki/Q103824","display_name":"Hematology","level":2,"score":0.2535000145435333},{"id":"https://openalex.org/C2992092908","wikidata":"https://www.wikidata.org/wiki/Q45959","display_name":"Drug toxicity","level":3,"score":0.25220000743865967}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1016/s2152-2650(26)02850-8","doi":"https://doi.org/10.1016/s2152-2650(26)02850-8","is_oa":false,"landing_page_url":"https://doi.org/10.1016/s2152-2650(26)02850-8","pdf_url":null,"source":{"id":"https://openalex.org/S186546955","display_name":"Clinical Lymphoma Myeloma & Leukemia","issn_l":"2152-2669","issn":["2152-2669","2152-2650"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Lymphoma Myeloma and Leukemia","raw_type":"journal-article"},{"id":"doi:10.21203/rs.3.rs-9707641/v1","doi":"https://doi.org/10.21203/rs.3.rs-9707641/v1","is_oa":true,"landing_page_url":"https://doi.org/10.21203/rs.3.rs-9707641/v1","pdf_url":"https://www.researchsquare.com/article/rs-9707641/latest.pdf","source":{"id":"https://openalex.org/S4306525896","display_name":"Research Square","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Research Square","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.21203/rs.3.rs-9707641/v1","doi":"https://doi.org/10.21203/rs.3.rs-9707641/v1","is_oa":true,"landing_page_url":"https://doi.org/10.21203/rs.3.rs-9707641/v1","pdf_url":"https://www.researchsquare.com/article/rs-9707641/latest.pdf","source":{"id":"https://openalex.org/S4306525896","display_name":"Research Square","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Research Square","raw_type":"posted-content"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7204691393.pdf","grobid_xml":"https://content.openalex.org/works/W7204691393.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W3118615836","https://openalex.org/W4281777449","https://openalex.org/W4378800539","https://openalex.org/W4385644723","https://openalex.org/W4385839624","https://openalex.org/W4386757223","https://openalex.org/W4388662093","https://openalex.org/W4389233437","https://openalex.org/W4392360934","https://openalex.org/W4402836453","https://openalex.org/W4404823295","https://openalex.org/W4406249309","https://openalex.org/W4408392330","https://openalex.org/W4409249692","https://openalex.org/W4413273659","https://openalex.org/W4413884488","https://openalex.org/W4414398065","https://openalex.org/W4414420388","https://openalex.org/W4415995326","https://openalex.org/W4416088402","https://openalex.org/W7130817776"],"related_works":["https://openalex.org/W7164333390","https://openalex.org/W7134964001","https://openalex.org/W7204732370","https://openalex.org/W4417017935","https://openalex.org/W4405039262","https://openalex.org/W4413994593","https://openalex.org/W7204706348","https://openalex.org/W7140194069","https://openalex.org/W4417018227","https://openalex.org/W4410800327"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Bispecific":[2],"antibodies":[3],"(BsAbs)":[4],"targeting":[5],"BCMA":[6],"(teclistamab,":[7],"elranatamab)":[8],"and":[9,47,96,121,139,159,172,183,244,315,368,393,426],"GPRC5D":[10],"(talquetamab)":[11],"have":[12,374],"transformed":[13],"relapsed/refractory":[14],"multiple":[15],"myeloma":[16],"(RRMM),":[17],"achieving":[18],"overall":[19],"response":[20,65,160,225,348],"rates":[21],"(ORR)":[22],"of":[23,41,83,119,176,223,232,275,282,313,319,347,365,410],"61\u201370%":[24],"in":[25,39,86,102,147,229,279,370],"heavily":[26],"pretreated":[27],"patients.":[28],"However,":[29,397],"standard":[30,93],"weekly":[31,94,217,243],"dosing":[32,55,79,146,361],"is":[33],"associated":[34,100],"with":[35,92,149,200,265,287,322,333,406],"grade":[36,168,288,323],"\u22653":[37,169,324],"infections":[38,257,290,325],"45\u201355%":[40],"recipients,":[42],"driven":[43],"by":[44],"prolonged":[45],"hypogammaglobulinemia":[46],"T\u2011cell":[48],"exhaustion.":[49],"Emerging":[50],"evidence":[51,399],"suggests":[52],"that":[53],"reducing":[54],"frequency":[56],"to":[57,97,192,218,261,294,350,418],"every":[58],"2":[59],"or":[60,81,363],"4":[61],"weeks":[62],"after":[63,162,220,272,296],"deep":[64],"may":[66],"preserve":[67],"efficacy":[68,90,152,380],"while":[69,381],"curbing":[70],"infectious":[71],"toxicity.":[72],"Objective:":[73],"To":[74],"systematically":[75],"evaluate":[76],"whether":[77],"reduced\u2011frequency":[78],"(Q2W":[80,362],"Q4W)":[82,364],"FDA\u2011approved":[84],"BsAbs":[85],"RRMM":[87,371],"maintains":[88],"clinical":[89],"compared":[91],"dosing,":[95],"quantify":[98],"the":[99,181,184,242,303,398],"reduction":[101],"infection\u2011related":[103],"adverse":[104],"events.":[105],"Methods:":[106],"A":[107],"PRISMA\u2011guided":[108],"systematic":[109],"review":[110],"was":[111,178,189],"conducted.":[112],"PubMed,":[113],"Embase,":[114],"Scopus,":[115],"Cochrane":[116],"CENTRAL,":[117],"Web":[118],"Science,":[120],"major":[122],"hematology":[123],"conference":[124],"proceedings":[125],"(ASH,":[126],"ASCO,":[127],"EHA,":[128],"SOHO;":[129],"2022\u20132026)":[130],"were":[131,134,154,167,211],"searched.":[132],"Included":[133],"prospective":[135],"trials,":[136],"cohort":[137],"studies,":[138,205],"post":[140],"hoc":[141],"analyses":[142],"reporting":[143],"reduced-frequency":[144,245],"BSAb":[145],"adults":[148],"RRMM.":[150],"Primary":[151],"outcomes":[153,166],"ORR,":[155],"progression\u2011free":[156],"survival":[157],"(PFS),":[158],"maintenance":[161,271,395],"dose":[163,254,351],"reduction.":[164],"Secondary":[165],"infections,":[170],"hypogammaglobulinemia,":[171],"treatment":[173],"discontinuation.":[174],"Risk":[175],"bias":[177,355],"assessed":[179],"using":[180],"ROBINS-I":[182],"Newcastle-Ottawa":[185],"Scale.":[186],"Narrative":[187],"synthesis":[188],"performed":[190],"due":[191],"heterogeneity.":[193],"Results:":[194],"Fourteen":[195],"studies":[196],"(three":[197],"pivotal":[198],"trials":[199,414],"de\u2011escalation":[201],"cohorts,":[202],"six":[203],"real\u2011world":[204],"five":[206],"sub\u2011analyses)":[207],"comprising":[208],">1,200":[209],"patients":[210,233,283,372],"included.":[212],"For":[213,268,301],"teclistamab,":[214,366],"transition":[215,298],"from":[216,259,292,402],"Q2W":[219,266,276,305],"\u22656":[221,273],"months":[222],"complete":[224],"(CR)":[226],"preserved":[227],"responses":[228,278,378],"100%":[230],"(37/37)":[231],"(MajesTEC\u20111).":[234],"Real-world":[235],"data":[236],"showed":[237],"comparable":[238],"median":[239,317],"PFS":[240,318],"between":[241],"groups":[246],"(9.1":[247],"vs":[248],"11.3":[249],"months;":[250],"p=0.141),":[251],"despite":[252],"lower":[253,329],"intensity.":[255],"All-grade":[256],"declined":[258],"6.08":[260],"2.25":[262],"per":[263],"patient-year":[264],"dosing.":[267],"elranatamab,":[269,367],"Q4W":[270,297],"cycles":[274],"maintained":[277],"92.6%":[280],"(25/27)":[281],"at":[284,326],"6":[285],"months,":[286,321],"3\u20134":[289],"decreasing":[291],"17.9%":[293],"10.7%":[295],"(Pfizer,":[299],"2025).":[300,339],"talquetamab,":[302],"FDA-approved":[304],"primary":[306],"schedule":[307],"(0.8":[308],"mg/kg)":[309],"achieved":[310,375],"an":[311],"ORR":[312],"71%":[314],"a":[316,407],"11.2":[320],"21%,":[327],"substantially":[328,382],"than":[330],"those":[331],"observed":[332],"BCMA-targeted":[334],"agents":[335],"(Chari":[336],"et":[337],"al.,":[338],"Across":[340],"all":[341],"agents,":[342],"no":[343],"study":[344],"reported":[345],"loss":[346],"attributable":[349],"de\u2011escalation,":[352],"but":[353],"selection":[354,424],"limits":[356],"causal":[357],"inference.":[358],"Conclusion:":[359],"Reduced\u2011frequency":[360],"talquetamab":[369],"who":[373],"deep,":[376],"sustained":[377],"preserves":[379],"lowering":[383],"infection":[384],"rates.":[385],"These":[386],"findings":[387],"support":[388],"regulatory":[389],"approvals":[390],"for":[391],"biweekly":[392],"monthly":[394],"schedules.":[396],"remains":[400],"derived":[401],"non-randomized,":[403],"single-arm":[404],"cohorts":[405],"moderate":[408],"risk":[409],"bias.":[411],"Prospective":[412],"randomized":[413],"are":[415],"urgently":[416],"needed":[417],"define":[419],"optimal":[420],"de-escalation":[421],"timing,":[422],"patient":[423],"biomarkers,":[425],"comparative":[427],"value":[428],"against":[429],"fixed-duration":[430],"CAR":[431],"T":[432],"therapy.":[433]},"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-08-31T00:00:00"}